Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EHC
EHC logo

EHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
107.095
Open
106.290
VWAP
106.50
Vol
607.30K
Mkt Cap
10.56B
Low
106.120
Amount
64.67M
EV/EBITDA(TTM)
9.99
Total Shares
99.42M
EV
13.79B
EV/OCF(TTM)
11.72
P/S(TTM)
1.83
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
Show More

Events Timeline

(ET)
2026-03-18
16:50:00
Encompass Health to Build 40-Bed Rehabilitation Hospital in Delaware
select
2026-02-13 (ET)
2026-02-13
08:10:00
Encompass Health to Build 50-Bed Rehab Hospital in Mississippi
select
2026-02-12 (ET)
2026-02-12
09:30:00
Enhabit and Encompass Health Awarded $43.1M
select
2026-02-05 (ET)
2026-02-05
20:00:00
Amazon Falls Over 10% After Earnings Report
select
2026-02-05
16:40:00
Sees FY26 Revenue at $6.365B-$6.465B
select
2026-02-05
16:30:00
Company Reports Q4 Revenue of $1.54B
select
2025-12-02 (ET)
2025-12-02
21:30:00
Bitcoin Rebounds Supporting Market Stabilization; Multiple Companies Release Earnings
select
2025-12-02
12:11:00
Banco Santander Sells 3.5% Stake in Santander Bank Polska for $473.1M
select
link
2025-12-01 (ET)
2025-12-01
16:40:00
Encompass Health Affirms FY25 Revenue Guidance of $5.905B-$5.955B
select

News

CNBC
2.0
04-20CNBC
Marion Jones Returns to Boston Marathon After Rare Disease Recovery
  • Rare Disease Diagnosis: Marion Jones was ultimately diagnosed with Neuromyelitis Optica (NMO) after multiple medical consultations, a rare autoimmune disorder that affects the optic nerves and spinal cord, leading to partial paralysis and a significant decline in her quality of life.
  • Challenging Rehabilitation: At Encompass Rehabilitation Hospital, Jones underwent three hours of intensive therapy daily, and through her dedication, she progressed from being wheelchair-bound to using a walker, showcasing remarkable recovery progress.
  • Reviving Running Aspirations: During an outpatient therapy session, Jones was challenged to run on a treadmill, managing only 30 seconds initially, but this reignited her passion for running, allowing her to gradually increase her distance from one minute to a mile, rekindling her athletic dreams.
  • Victory at Boston Marathon: Jones is set to complete the Boston Marathon, earning the Abbott World Marathon Majors Six Star Finisher Medal, symbolizing her triumph over adversity, while also raising funds for the rare disease community, reflecting her resilience and commitment to advocacy.
Globenewswire
7.0
04-14Globenewswire
Pomerantz LLP Investigates Encompass Health Securities Fraud Claims
  • Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation, focusing on whether its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
  • Safety Issues Exposed: An article by The New York Times reported that Encompass-operated for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly higher rates of preventable readmissions, potentially triggering regulatory scrutiny and legal liabilities.
  • Significant Stock Drop: Following the publication of the report, Encompass's stock price fell by $12.39 on July 15, 2025, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns over the company's operational safety.
  • Potential Legal Consequences: This investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking damages for affected investors, further impacting the company's reputation and financial standing.
Globenewswire
7.0
04-07Globenewswire
Pomerantz LLP Investigates Encompass Health Securities Fraud Claims
  • Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation and its executives for potential securities fraud or other unlawful business practices, which may lead to significant investor losses.
  • Safety Issues Exposed: An article published by The New York Times on July 15, 2025, alleged that for-profit hospitals operated by Encompass perform below average on key safety measures, with 34 facilities rated as having significantly higher rates of preventable readmissions, potentially undermining investor confidence.
  • Stock Price Plunge: Following the publication of the article, Encompass's stock price fell by $12.39, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns regarding the safety of the company's operations.
  • Potential Legal Action: The investigation by Pomerantz LLP may lead to a class action lawsuit, with investors encouraged to contact the firm to explore joining the action, which could further impact Encompass's market performance.
PRnewswire
9.5
04-07PRnewswire
Encompass Health to Report Q1 2026 Results on April 30
  • Earnings Announcement Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, demonstrating the company's commitment to financial transparency, which is expected to positively impact investor confidence.
  • Investor Conference Call: The company will host an investor conference call on May 1, 2026, at 10 a.m. ET to discuss its results, providing access via 800-267-6316, ensuring timely information dissemination to investors.
  • Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, showcasing its leadership and market influence in the rehabilitation healthcare sector.
  • Industry Recognition: The company is recognized as America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista, and ranks among Fortune's World's Most Admired Companies™, further solidifying its reputation and appeal in the healthcare industry.
Newsfilter
9.5
04-07Newsfilter
Encompass Health to Report Q1 2026 Results on April 30
  • Earnings Release Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, providing key financial metrics and operational performance insights that will help investors assess the company's future growth potential.
  • Investor Conference Call: The company will host an investor conference call at 10 a.m. ET on May 1, 2026, to discuss the earnings results, which is expected to attract significant attention from analysts and investors, thereby enhancing market transparency.
  • Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, demonstrating its leadership position in the healthcare sector by providing high-quality rehabilitative care.
  • Industry Recognition: The company has been recognized by Newsweek and Statista as America's Most Awarded Leader in Inpatient Rehabilitation and ranks among Fortune's World's Most Admired Companies and Forbes' America's Best Companies, reflecting its strong reputation and competitive advantage in the industry.
CNBC
2.0
04-06CNBC
AppLovin Shares Surge 5% on Bullish Wall Street Reports
  • AppLovin Revenue Upgrade: BTIG raised AppLovin's first-quarter revenue estimate to $1.82 billion, exceeding consensus, reflecting healthier performance from non-gaming marketers, which is expected to drive further stock price appreciation.
  • Encompass Health Surge: Shares of Encompass Health jumped over 6% after the Centers for Medicare & Medicaid Services proposed a 2.4% rate increase for fiscal year 2027, indicating positive policy changes for the healthcare sector.
  • Kratos Defense Rallies 8%: Jefferies upgraded Kratos from hold to buy with a 12-month price target of $85, highlighting a $14 billion opportunity pipeline in weapons that could drive over 30% compound annual growth in 2028 earnings estimates.
  • Soleno Therapeutics Soars 32%: Neurocrine Biosciences announced an agreement to acquire Soleno for $53 per share, valuing the deal at approximately $2.9 billion, which will enhance Neurocrine's leadership in endocrinology and rare diseases.
Wall Street analysts forecast EHC stock price to rise
5 Analyst Rating
Wall Street analysts forecast EHC stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
134.00
Averages
146.75
High
160.00
Current: 0.000
sliders
Low
134.00
Averages
146.75
High
160.00
Barclays
NULL -> Overweight
maintain
$150 -> $153
AI Analysis
2026-02-06
Reason
Barclays
Price Target
$150 -> $153
AI Analysis
2026-02-06
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Encompass Health to $153 from $150 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 report.
Barclays
Andrew Mok
Overweight
maintain
$141 -> $150
2025-10-30
Reason
Barclays
Andrew Mok
Price Target
$141 -> $150
2025-10-30
maintain
Overweight
Reason
Barclays analyst Andrew Mok raised the firm's price target on Encompass Health to $150 from $141 and keeps an Overweight rating on the shares. The company reported a modest Q4 beat, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Encompass Health Corp (EHC.N) is 17.06, compared to its 5-year average forward P/E of 19.32. For a more detailed relative valuation and DCF analysis to assess Encompass Health Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
19.32
Current PE
17.06
Overvalued PE
21.39
Undervalued PE
17.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.85
Current EV/EBITDA
8.21
Overvalued EV/EBITDA
11.92
Undervalued EV/EBITDA
9.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.49
Current PS
1.53
Overvalued PS
1.74
Undervalued PS
1.24

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what other stocks should I buy and why
Intellectia · 14 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 35Target Price Upside Potential: MoreAbovePriceOne Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
PTC logo
PTC
PTC Inc
19.39B
MSFT logo
MSFT
Microsoft Corp
3.01T
NVO logo
NVO
Novo Nordisk A/S
171.90B
SEIC logo
SEIC
SEI Investments Co
10.00B
BMRN logo
BMRN
BioMarin Pharmaceutical Inc
11.62B
BR logo
BR
Broadridge Financial Solutions Inc
22.04B
what are the best stocks to buy today
Intellectia · 16 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.65T
PDD logo
PDD
PDD Holdings Inc
150.14B
QCOM logo
QCOM
Qualcomm Inc
149.82B
SMFG logo
SMFG
Sumitomo Mitsui Financial Group, Inc
148.10B
SNY logo
SNY
Sanofi SA
114.04B
CEG logo
CEG
Constellation Energy Corp
106.46B
what stock to buy Monday
Intellectia · 5 candidates
Market Cap: >= 10.00BBeta: LowRisk, ModerateRiskWeekly Average Turnover: >= 1,000,000Rsi 14: <= 35Week Price Change Pct: >= $-1.00
Ticker
Name
Market Cap$
top bottom
ET logo
ET
Energy Transfer LP
60.60B
MPLX logo
MPLX
MPLX LP
56.57B
PAA logo
PAA
Plains All American Pipeline LP
13.48B
YMM logo
YMM
Full Truck Alliance Co Ltd
10.30B
EHC logo
EHC
Encompass Health Corp
10.00B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B
share the top 100 instead of 12
Intellectia · 24 candidates
Market Cap: >= 1000.00MNet Margin: >= 10.00Weekly Average Turnover: >= 1,000,000Pe Ttm: 17 - 23Return On Equity: >= 18.0%Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
NVS logo
NVS
Novartis AG
278.44B
COIN logo
COIN
Coinbase Global Inc
61.19B
AU logo
AU
Anglogold Ashanti PLC
51.18B
KGC logo
KGC
Kinross Gold Corp
43.05B
FUTU logo
FUTU
Futu Holdings Ltd
23.11B
FTI logo
FTI
TechnipFMC PLC
21.93B

Whales Holding EHC

O
Oberweis Asset Management, Inc.
Holding
EHC
+44.05%
3M Return
L
Leeward Investments, LLC
Holding
EHC
+23.97%
3M Return
S
Systematic Financial Management LP
Holding
EHC
+14.06%
3M Return
F
Fuller & Thaler Asset Management, Inc.
Holding
EHC
+12.38%
3M Return
R
Reinhart Partners, LLC
Holding
EHC
+10.85%
3M Return
C
Copeland Capital Management, LLC
Holding
EHC
+7.60%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Encompass Health Corp (EHC) stock price today?

The current price of EHC is 106.27 USD — it has decreased -0.11

What is Encompass Health Corp (EHC)'s business?

Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.

What is the price predicton of EHC Stock?

Wall Street analysts forecast EHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHC is146.75 USD with a low forecast of 134.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Encompass Health Corp (EHC)'s revenue for the last quarter?

Encompass Health Corp revenue for the last quarter amounts to 1.54B USD, increased 9.94

What is Encompass Health Corp (EHC)'s earnings per share (EPS) for the last quarter?

Encompass Health Corp. EPS for the last quarter amounts to 1.43 USD, increased 21.19

How many employees does Encompass Health Corp (EHC). have?

Encompass Health Corp (EHC) has 24611 emplpoyees as of April 21 2026.

What is Encompass Health Corp (EHC) market cap?

Today EHC has the market capitalization of 10.56B USD.